Brind.
  1. Major institutional investors, including BlackRock, Man Group, and BNY Mellon, acquired new stakes on October 31, 2026.

Institutional Investors Increase Stakes in Coherus Oncology Stock

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

On October 31, 2026, Renaissance Technologies increased its financial stake in Coherus Oncology. This activity occurred amid a decline in the company's short interest during October, which dropped 46.6% from the September 30th total. Analysts have issued mixed ratings, with one brokerage issuing a "buy" rating while another upgraded its rating from a "sell (e+)" to a "sell (d-)" in a research report.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The increased investment from major financial firms, coupled with a decline in short interest, suggests growing institutional confidence in Coherus Oncology. This activity occurs as other major institutional investors, including Man Group and BNY Mellon, also acquired new stakes on October 31, 2026.

Major institutional investors, including BlackRock, Man Group, and BNY Mellon, acquired new stakes on October 31, 2026.

From themarketsdaily.com

Who's involved

Keep exploring

Part of

Major institutional investors, including BlackRock, Man Group, and BNY Mellon, acquired new stakes on October 31, 2026. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped